| scholarly article | Q13442814 |
| P2093 | author name string | Clara Hwang | |
| Amanda B Pilling | |||
| P2860 | cites work | IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling | Q38714695 |
| The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models | Q38736457 | ||
| Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer | Q39139830 | ||
| The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance | Q39227285 | ||
| TNF-alpha-induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-X(L). | Q39732156 | ||
| Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. | Q40263616 | ||
| A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies | Q46195208 | ||
| Neoadjuvant Enzalutamide Prior to Prostatectomy | Q46366990 | ||
| Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary. | Q54710973 | ||
| Activation of programmed cell death in the rat ventral prostate after castration | Q69816264 | ||
| Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition | Q88619003 | ||
| Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss | Q90424840 | ||
| Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer | Q24307748 | ||
| Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c | Q24309066 | ||
| Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members | Q24337108 | ||
| Therapy escape mechanisms in the malignant prostate | Q26795611 | ||
| BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions | Q26828031 | ||
| Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study | Q27313709 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. | Q27851702 | ||
| Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery | Q27860586 | ||
| The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB | Q33959407 | ||
| The androgen receptor mediates antiapoptotic function in myometrial cells | Q34007815 | ||
| Targeting apoptosis in prostate cancer | Q34348279 | ||
| Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
| Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). | Q35543223 | ||
| Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers | Q35773657 | ||
| Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 | Q35779325 | ||
| U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer | Q35915730 | ||
| Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma | Q36988067 | ||
| The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. | Q37035832 | ||
| Apoptosis and molecular targeting therapy in cancer | Q38228349 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 11 | |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1347-1359 | |
| P577 | publication date | 2019-06-22 | |
| P1433 | published in | The Prostate | Q7758608 |
| P1476 | title | Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide | |
| P478 | volume | 79 |
| Q93155378 | Dual role of Endoplasmic Reticulum Stress-Mediated Unfolded Protein Response Signaling Pathway in Carcinogenesis |
| Q99551795 | Resveratrol inhibits proliferation and promotes apoptosis via the androgen receptor splicing variant 7 and PI3K/AKT signaling pathway in LNCaP prostate cancer cells |
| Q94464833 | Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells |
Search more.